- Home
- EKSO vs KPRX Comparison
EKSO vs KPRX Comparison
Compare EKSO & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EKSO
- KPRX
- Stock Information
- Founded
- EKSO 2005
- KPRX 1998
- Country
- EKSO United States
- KPRX United States
- Employees
- EKSO N/A
- KPRX N/A
- Industry
- EKSO Medical/Dental Instruments
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EKSO Health Care
- KPRX Health Care
- Exchange
- EKSO Nasdaq
- KPRX Nasdaq
- Market Cap
- EKSO 7.7M
- KPRX 9.2M
- IPO Year
- EKSO N/A
- KPRX N/A
- Fundamental
- Price
- EKSO $4.95
- KPRX $2.48
- Analyst Decision
- EKSO Strong Buy
- KPRX Strong Buy
- Analyst Count
- EKSO 2
- KPRX 1
- Target Price
- EKSO $34.75
- KPRX $10.00
- AVG Volume (30 Days)
- EKSO 47.1K
- KPRX 48.4K
- Earning Date
- EKSO 10-28-2025
- KPRX 11-07-2025
- Dividend Yield
- EKSO N/A
- KPRX N/A
- EPS Growth
- EKSO N/A
- KPRX N/A
- EPS
- EKSO N/A
- KPRX N/A
- Revenue
- EKSO $14,749,000.00
- KPRX N/A
- Revenue This Year
- EKSO N/A
- KPRX N/A
- Revenue Next Year
- EKSO $49.96
- KPRX N/A
- P/E Ratio
- EKSO N/A
- KPRX N/A
- Revenue Growth
- EKSO N/A
- KPRX N/A
- 52 Week Low
- EKSO $2.73
- KPRX $2.21
- 52 Week High
- EKSO $15.45
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- EKSO 54.44
- KPRX 43.65
- Support Level
- EKSO $4.61
- KPRX $2.21
- Resistance Level
- EKSO $5.44
- KPRX $2.65
- Average True Range (ATR)
- EKSO 0.38
- KPRX 0.15
- MACD
- EKSO -0.03
- KPRX -0.01
- Stochastic Oscillator
- EKSO 59.49
- KPRX 48.42
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.